NeuroAdjuvants Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

NeuroAdjuvants General Information

Description

Developer of peptide-based therapeutics intended to offer therapeutics for neurological treatment. The company's peptide-based therapeutics is produced by research and development of neuropeptide-based therapeutics for the treatment of neurological, psychiatric, metabolic and inflammatory disorders, enabling healthcare sectors to provide proper treatment for neurological diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 417 Wakara Way
  • Suite 3510
  • Salt Lake City, UT 84108
  • United States
+1 (801)
Primary Industry
Biotechnology
Corporate Office
  • 417 Wakara Way
  • Suite 3510
  • Salt Lake City, UT 84108
  • United States
+1 (801)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroAdjuvants Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 29-Nov-2018 Completed Out of Business
3. Grant 26-Mar-2009 Completed Startup
2. Early Stage VC (Series A2) 27-Jun-2007 $1000K $1.2M Completed Startup
1. Early Stage VC (Series A1) 22-Jan-2007 $200K $200K Completed Startup
To view NeuroAdjuvants’s complete valuation and funding history, request access »

NeuroAdjuvants Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A2
Series A1
To view NeuroAdjuvants’s complete cap table history, request access »

NeuroAdjuvants Patents

  • 10

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • Pending

  • Expiring in next 12 mo

NeuroAdjuvants Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160367554-A1 Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use Active 21-Jan-2014
US-10537573-B2 Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use Active 21-Jan-2014
AU-2011343822-A1 Neuropeptide analogs, compositions, and methods for treating pain Active 15-Dec-2010
CA-2858811-A1 Neuropeptide analogs, compositions, and methods for treating pain Inactive 15-Dec-2010
US-20130324467-A1 Neuropeptide analogs, compositions, and methods for treating pain Inactive 15-Dec-2010 A61K38/10
To view NeuroAdjuvants’s complete patent history, request access »

Ready to get started?

Request a free trial

NeuroAdjuvants FAQs

  • When was NeuroAdjuvants founded?

    NeuroAdjuvants was founded in 2005.

  • Where is NeuroAdjuvants headquartered?

    NeuroAdjuvants is headquartered in Salt Lake City, UT.

  • What industry is NeuroAdjuvants in?

    NeuroAdjuvants’s primary industry is Biotechnology.

  • Is NeuroAdjuvants a private or public company?

    NeuroAdjuvants is a Private company.

  • What is NeuroAdjuvants’s current revenue?

    The current revenue for NeuroAdjuvants is .

  • How much funding has NeuroAdjuvants raised over time?

    NeuroAdjuvants has raised $1.2M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »